STOCK TITAN
  1. Home
  2. News
  3. BCRX

BioCryst to Present at Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

RESEARCH TRIANGLE PARK, N.C., April 12, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the following investor conferences:

  • The 22nd Annual Needham Virtual Healthcare Conference on Wednesday, April 19th at 8:45 a.m. ET
  • The BofA Securities 2023 Health Care Conference in Las Vegas on Wednesday, May 10th at 6:00 p.m. ET
  • The JMP Securities Life Sciences Conference in New York on Tuesday, May 16th at 2:30 p.m. ET
  • The RBC Capital Markets Global Healthcare Conference in New York on Wednesday, May 17th at 8:00 a.m. ET

Links to the live audio webcasts and replays of the presentations may be accessed in the Investors & Media section of BioCryst’s website at http://www.biocryst.com.

About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO® (berotralstat) is approved in the United States and many global markets. BioCryst has active programs to develop oral medicines for multiple targets across the complement system, including BCX10013, an oral Factor D inhibitor in clinical development. RAPIVAB® (peramivir injection) is approved in the U.S. and multiple global markets, with post-marketing commitments ongoing. For more information, please visit the company’s website at www.biocryst.com.

BCRXW

Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com

 


Stock BCRX logo
BioCryst Pharmaceuticals, Inc.

NASDAQ:BCRX

BCRX Rankings

#2286 Ranked by Market Cap
#4914 Ranked by Stock Gains
N/A Ranked by Dividends

BCRX Latest News

May 14, 2024
BioCryst to Present New Data at 2024 Meeting of the European Academy of Allergy and Clinical Immunology
May 13, 2024
ORLADEYO® (berotralstat) Approved in Mexico
May 9, 2024
BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO® (berotralstat)
May 7, 2024
BioCryst to Present at Upcoming Investor Conferences
May 6, 2024
BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update

BCRX Stock Data

1.27B
190.88M
1.21%
88.11%
15.65%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
DURHAM

About BCRX

biocryst pharmaceuticals, a biotechnology company, designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and rare diseases. founded in 1986, biocryst has more than 50 employees and is experiencing continued growth. the company’s headquarters are located in research triangle park, north carolina and its discovery center of excellence is in birmingham, alabama. with expertise in drug discovery, clinical development, regulatory affairs and product commercialization, we continue to advance our clinical programs and to generate new compounds from our own discovery engine. we are proud of our culture of engagement and accountability that rewards people for innovative thinking and achievement of key objectives. the commitment of biocryst remains unchanged. we continue to be passionate about developing and marketing novel therapeutics for patients with rare and serious diseases.